RT Journal Article
T1 Plasma concentrations of neurofilament light chain protein and brain-derived neurotrophic factor as consistent biomarkers of cognitive impairment in alcohol use disorder
A1 Requena Ocaña, Nerea
A1 Araos, Pedro
A1 Serrano Castro, Pedro J.
A1 Flores López, María
A1 García Marchena, Nuria
A1 Oliver Martos, Begoña
A1 Ruiz, Juan Jesús
A1 Gavito, Ana
A1 Pavón Carrasco, Francisco Javier
A1 Serrano, Antonia
A1 Mayoral, Fermín
A1 Suarez, Juan
A1 Rodríguez De Fonseca, Fernando Antonio
AB For a long time, Substance Use Disorders (SUDs) were not considered a component in the etiology of dementia. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders introduced substance-induced neurocognitive disorders, incorporating this notion to clinical practice. However, detection and monitoring of neurodegenerative processes in SUD patients remain a major clinical challenge, especially when early diagnosis is required. In the present study, we aimed to investigate new potential biomarkers of neurodegeneration that could predict cognitive impairment in SUD patients: the circulating concentrations of Neurofilament Light chain protein (NfL) and Brain-Derived Neurotrophic Factor (BDNF). Sixty SUD patients were compared with twenty-seven dementia patients and forty healthy controls. SUD patients were recruited and assessed using the Psychiatric Research Interview for Substance and Mental (PRISM) and a battery of neuropsychological tests, including the Montreal Cognitive Assessment test for evaluation of cognitive impairment. When compared to healthy control subjects, SUD patients showed increases in plasma NfL concentrations and NfL/BDNF ratio, as well as reduced plasma BDNF levels. These changes were remarkable in SUD patients with moderate–severe cognitive impairment, being comparable to those observed in dementia patients. NfL concentrations correlated with executive function and memory cognition in SUD patients. The parameters “age”, “NfL/BDNF ratio”, “first time alcohol use”, “age of onset of alcohol use disorder”, and “length of alcohol use disorder diagnosis” were able to stratify our SUD sample into patients with cognitive impairment from those without cognitive dysfunction with great specificity and sensibility. In conclusion, we propose the combined use of NfL and BDNF (NfL/BDNF ratio) to monitor substance-induced neurocognitive disorder.
PB MDPI
SN 1422-0067
YR 2023
FD 2023-01-07
LK https://hdl.handle.net/20.500.14352/105032
UL https://hdl.handle.net/20.500.14352/105032
LA eng
NO Requena-Ocaña, N.; Araos, P.; Serrano-Castro, P.J.; Flores-López, M.; García-Marchena, N.; Oliver-Martos, B.; Ruiz, J.J.; Gavito, A.; Pavón, F.J.; Serrano, A.; et al. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder. Int. J. Mol. Sci. 2023, 24, 1183. https://doi.org/10.3390/ijms24021183
NO 2023 Descuento MDPI
DS Docta Complutense
RD 9 abr 2025